|
|
The Cooper Companies Inc (COO) |
|
Price: $335.0600
$-4.28 
-1.261%
|
| Day's High:
| $338.75
| Week Perf:
| -0.87 %
|
| Day's Low: |
$ 334.64 |
30 Day Perf: |
8.84 % |
| Volume (M): |
360 |
52 Wk High: |
$ 399.62 |
| Volume (M$): |
$ 120,488 |
52 Wk Avg: |
$352.75 |
| Open: |
$336.60 |
52 Wk Low: |
$303.74 |
|
|
| Market Capitalization (Millions $) |
16,719 |
| Shares
Outstanding (Millions) |
50 |
| Employees |
14,000 |
| Revenues (TTM) (Millions $) |
3,514 |
| Net Income (TTM) (Millions $) |
275 |
| Cash Flow (TTM) (Millions $) |
-129 |
| Capital Exp. (TTM) (Millions $) |
342 |
The Cooper Companies Inc
The Cooper Companies Inc is an American medical device company that specializes in ophthalmology and fertility. The company's history dates back to 1958 when it was founded by Martin Cooper to produce contact lenses under the name of 'Cooper Laboratories'. Over the years, the company has expanded its operations and it currently serves customers in more than 100 countries around the world.
Under its ophthalmology business, The Cooper Companies manufactures and markets a wide range of vision care products including soft contact lenses, silicone hydrogel lenses, toric lenses, multifocal lenses, and lens care solutions. The company's contact lenses are designed to address different eye conditions such as astigmatism, presbyopia, and myopia. Its primary brands include Biofinity, Avaira, Proclear, and Clariti.
In addition to its ophthalmology business, The Cooper Companies also has a fertility business that produces products designed to aid couples in becoming pregnant. This business primarily focuses on developing and selling medical devices and consumables for assisted reproductive technologies, such as in-vitro fertilization (IVF). The Cooper Companies is a leader in this market with a strong presence in the US, Europe, and Japan.
The Cooper Companies operates in two primary segments: CooperVision and CooperSurgical. CooperVision includes the company's vision care operations, while CooperSurgical encompasses its fertility products and services. These two segments are managed by different leadership teams within the company.
The Cooper Companies has made several strategic acquisitions over the years to expand its product portfolio and global reach. In 2014, the company acquired Sauflon Pharmaceuticals, a UK-based contact lens manufacturer, to strengthen its position in the European market. In 2017, it acquired the assets of Teva Pharmaceutical's global women's health business, making it one of the largest women's health companies in the world.
The company has a diversified customer base, which includes eye care professionals, hospitals, clinics, and retail stores. The Cooper Companies also operates its own e-commerce channel through which patients can purchase contact lenses directly from the company.
The corporate headquarters of The Cooper Companies is located in San Ramon, California. The company has a global footprint, with manufacturing and distribution facilities located in the United States, Europe, and Asia. The company employs more than 12,000 people worldwide and reported a revenue of $2.6 billion in FY2020.
Company Address: 6101 Bollinger Canyon Road San Ramon 94583 CA
Company Phone Number: 460-3600 Stock Exchange / Ticker: NYSE COO
| COO is expected to report next financial results on December 08, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Nocturne Acquisition Corporation
Nocturne Acquisition Corporation, a reputable player in the financial industry, recently announced its earnings for the third quarter of 2023. While the results indicate increased deficits per share compared to the previous year, it is important to consider the broader context and acknowledge positive shifts that may impact future financial performance. This article will explore the implications of these results and shed light on the potential for a bullish outlook for Nocturne Acquisition Corporation.
Increased Deficits Per Share:
The most notable aspect of the Q3 2023 earnings report is the increase in deficits per share. Nocturne Acquisition Corporation experienced a deficit per share of $-0.11, as opposed to $-0.03 from the preceding year. This indicates a decline in profitability on a per-share basis. Additionally, the deficit grew from $-0.02 per share in the preceding reporting season. These numbers suggest that Nocturne Acquisition Corporation faced challenges during this period.
|
|
Becton Dickinson And Company
Becton Dickinson And Company, a medical equipment and supplies company, recently released its financial results for the fourth quarter of 2023. The company reported an income per share of $0.37 and revenue of $4.88 billion during this period. While the revenue increased by 20.459% compared to the fourth quarter of 2022, the company's income per share declined from $0.92 to $0.37. This indicates that although Becton Dickinson And Company saw significant revenue growth, their profitability decreased.
However, when compared to other companies in the Medical Equipment and Supplies sector, Becton Dickinson And Company had a much higher top-line improvement during the fourth quarter of 2023. On average, companies in this sector reported a top-line improvement of 4.80% in comparison to the same period in 2022. In contrast, Becton Dickinson And Company experienced a revenue surge of 20.459%. This suggests that the company outperformed its industry peers in terms of revenue growth.
|
|
Iridex Corp
Iridex Corp, a leading medical equipment and supplies company, recently released its financial results for the third quarter of 2023 earnings season. While the company reported a net loss of $-0.11 per share, this is an improvement compared to the previous year's loss of $-0.17 per share. However, the revenue for the quarter declined significantly by -12.718% to $12.62 million, compared to $14.46 million in the same period a year ago.
This decline in revenue is in stark contrast to the overall trend in the Medical Equipment and Supplies sector, which saw a top-line gain during the same period. The company's management has not provided specific reasons for this decline, but some experts speculate that it may be due to slowing demand or other market factors.
|
|
Digital Health Acquisition Corp
/>In the medical equipment and supplies sector, industry analysts are closely scrutinizing the third quarter financial performance of Digital Health Acquisition Corp (DHAC). With a reported operating loss of $-0.518084 million, the company has yet to disclose any top-line figures for the July to September 2023 reporting season. However, the current results reflect a significant improvement compared to the same period in 2022, where the operating loss stood at $-1.129361 million. This development serves as a key indicator for the company's overall situation.
Growing Importance of Cost-Effectiveness in the Market:
For emerging growth entities such as DHAC, developing sustainable revenue sources is crucial to advancing to the next phase. Consequently, cost-effectiveness has become a vital aspect for these companies to remain competitive in the industry. Despite DHAC's efforts to prompt revenue sources, it is noteworthy that the company achieved not only a net profit of $0.078 million but also outperformed its Q3 2022 results.
|
|
Nuo Therapeutics Inc
Nuo Therapeutics Inc: A Bullish Outlook for Future Growth
Nuo Therapeutics Inc, a leading Medical Equipment and Supplies company, recently reported third-quarter earnings that exceeded industry expectations. With a remarkable revenue rise of 507.166% year on year to $0.23 million, Nuo Therapeutics has demonstrated its robustness and resilience in the market. Although the company experienced a loss at $-0.02 per share, its strong revenue growth far outweighs this setback.
When compared to its industry peers, Nuo Therapeutics has clearly outperformed. The Medical Equipment and Supplies industry, as a whole, has averaged a revenue increase of just 4.80% during the same period. This significant gap in revenue growth showcases Nuo Therapeutics' ability to outshine its competitors and solidify its position as a market leader.
|
| Per Share |
Current |
| Earnings (TTM) |
5.53 $ |
| Revenues (TTM) |
70.42 $
|
| Cash Flow (TTM) |
- |
| Cash |
2.35 $
|
| Book Value |
150.87 $
|
| Dividend (TTM) |
0.06 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
5.53 $
|
| Revenues (TTM) |
70.42 $ |
| Cash Flow (TTM) |
- |
| Cash |
2.35 $
|
| Book Value |
150.87 $ |
| Dividend (TTM) |
0.06 $ |
|
|
|
|
